


# Financial Tear Sheet

## Corporate Profile

Who is Organovo?

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong IP portfolio
- We're leveraging our technology platform to build a robust product and service platform across the high-value drug profiling and therapeutic tissues markets

 [2017 Annual Report](#)    [Investor Presentation](#)

## Stock Information

ONVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	<b>\$1.18</b>
Change (%)	<b>▲ 0.06 (5.36%)</b>
Volume	801,218
52 Week Low	\$0.91
Market Cap	\$130,786,448
Rolling EPS	-0.36
PE Ratio	0
Shares Outstanding	110,835,973
Data as of 04/20/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Primary IR Contact

Steve E. Kunszabo  
 VP, Investor Relations &  
 Corporate  
 Communications  
**Phone:** 858-224-1092  
**Email:**  
[skunszabo@organovo.com](mailto:skunszabo@organovo.com)

## Recent Press Releases & Upcoming Events

04/16/18

Organovo Achieves Key Development Milestones for Its Liver Disease and Intestinal Tissue Models

04/12/18

Organovo Presents Data on Modeling Liver Disease Using 3D Bioprinted Human Liver Tissue at The International Liver Congress™

03/26/18

Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
03/23/18	EFFECT
03/16/18	POS AM
03/16/18	424B5
03/16/18	8-K

## Corporate Governance

Taylor J. Crouch	President & Chief Executive Officer
Sharon Collins Presnell, Ph.D.	Chief Scientific Officer, Organovo & President, Samsara
Eric Michael David, M.D., J.D.	Chief Strategy Officer and Executive Vice President of Preclinical Development
Jennifer Kinsbruner Bush, J.D.	General Counsel, Corporate Secretary and Compliance Officer
Susan Daugherty	Senior Vice President, Human Resources
Paul Gallant	General Manager